This is a big one for our industry. Centinel Spine will be testing the public markets soon.
Below I will share everything you need to know about the S-1, just for you.
There are two interesting background stories to this new IPO. 1/ Fusion is flat. Disc arthroplasty is gaining.
Disc arthroplasty is the only spine pocket still compounding. Centinel sold the cages to Silony in 2023, kept prodisc, and is now the only U.S. franchise with one- and two-level PMA in both cervical and lumbar. H1 revenue $85.2 million, up 42%, gross margin about 82%. The IPO is a wager that surgeons keep converting fusions, not that Centinel invents a new category.
2/ The Viscogliosi round trip
Spine Solutions sold prodisc to Synthes for $350 million in 2003. Viscogliosi Brothers bought the worldwide assets back through Centinel in 2017. John Viscogliosi ran it until 2020, handed the seat to Steve Murray, and the same disc is now heading to the NYSE as CNTL. Thirty-plus years, 300,000 implants, one asset, three owners.
Ok, let's dive into the S-1 details now.
S-1 Filing Deep Dive
Company: Centinel Spine Holdco (Delaware corporation formed April 24, 2026; Up-C structure)
Ticker / Exchange: CNTL / NYSE
Fi...
